Ulster University Logo

Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?

Gault, Victor, O'Harte, Finbarr and Flatt, Peter (2003) Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? NEUROPEPTIDES, 37 (5). pp. 253-263. [Journal article]

Full text not available from this repository.

DOI: 10.1016/j.npep.2003.09.002


Glucose-dependent insulinotropic polypeptide (GIP or gastric inhibitory polypeptide) is a gastrointestinal hormone, which modulates physiological insulin secretion. Due to its insulinotropic activity, there has been a considerable increase of interest in utilising the hormone as a potential therapy for type 2 diabetes. One of the difficulties in attempting to harness the insulinotropic activity of GIP into an effective therapeutic agent is its short biological half-life in the circulation. However, recent years have witnessed the development of a substantial number of designer enzyme-resistant `super GIP' molecules with potent insulinotropic and anti-diabetic properties. In addition, observations in transgenic GIP receptor deficient mice indicate that GIP directly links overnutrition to obesity, therein playing a crucial role in the development of obesity and related metabolic disorders. The present review aims to highlight the rapidly emerging potential therapeutic applications of GIP, and especially, enzyme-resistant GIP analogues. (C) 2003 Elsevier Ltd. All rights reserved.

Item Type:Journal article
Faculties and Schools:Faculty of Life and Health Sciences
Faculty of Life and Health Sciences > School of Biomedical Sciences
Research Institutes and Groups:Biomedical Sciences Research Institute
Biomedical Sciences Research Institute > Diabetes
ID Code:3033
Deposited By: Professor Peter Flatt
Deposited On:14 Jan 2010 15:45
Last Modified:09 May 2016 10:48

Repository Staff Only: item control page